Precision BioSciences reports ~$137M cash, outlines 2026 clinical milestones for HBV and DMD programs

PRECISION BIOSCIENCES INC

Preliminary cash ~$137M as of Dec 31, 2025; cash runway expected through 2028.
PBGENE-HBV: Phase 1/2a ELIMINATE-B dosing Cohorts 3-5 ongoing; additional biopsy data expected H1 2026.
PBGENE-DMD: IND clearance expected Q1 2026; first patient dosing late-Q1/early-Q2 2026; initial data by year-end 2026.
Partnered programs: iECURE ECUR-506 RMAT designation; Imugene milestone $8M received; TG Therapeutics potential $7.5M milestone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.